ACTG 300 leaves many questions unanswered.
Gilden
D
D
D000293:Adolescent; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D016049:Didanosine / Q000627:therapeutic use; D018450:Disease Progression; D004359:Drug Therapy, Combination; D004992:Ethics, Medical; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007223:Infant; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D019259:Lamivudine; D015215:Zidovudine; D016049:Didanosine